

# PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

## **FORM 8-K** (Current report filing)

Filed 08/02/17 for the Period Ending 08/02/17

Address	1305 O'BRIEN DRIVE MENLO PARK, CA 94025
Telephone	650-521-8000
CIK	0001299130
Symbol	PACB
SIC Code	3826 - Laboratory Analytical Instruments
Industry	Advanced Medical Equipment & Technology
Sector	Healthcare
Fiscal Year	12/31

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  
August 2 , 2017

---

**Pacific Biosciences of California, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34899**  
(Commission  
File Number)

**16-1590339**  
(IRS Employer  
Identification No.)

**1305 O'Brien Drive**  
**Menlo Park, California 94025**  
(Address of principal executive offices, including zip code)

**(650) 521-8000**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

---

**ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.**

On August 2, 2017, Pacific Biosciences of California, Inc. announced its financial results for its second fiscal quarter ended June 30, 2017. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, "Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits.

99.1 Press Release dated August 2, 2017 titled "Pacific Biosciences of California, Inc. Announces Second Quarter 2017 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02).

---

---



## EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated August 2 , 2017 titled "Pacific Biosciences of California, Inc. Announces Second Quarter 2017 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02).

---

**Pacific Biosciences of California, Inc. Announces Second Quarter 2017 Financial Results**

*Product and Service Revenue Increases by 17 % Over Same Period in Previous Year*

**Menlo Park, Calif.** – August 2, 2017 – Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2017.

Product, service and other revenue for the second quarter of 2017 increased by 17% to \$20.1 million, compared to \$17.2 million for the second quarter of 2016. Total revenue for the second quarter of 2017 was \$20.1 million, compared to \$20.7 million for the second quarter of 2016. Total revenue for the second quarter of 2016 included \$3.6 million of contractual revenue, whereas the second quarter of 2017 included no contractual revenue.

Gross profit for the second quarter of 2017 was \$8.0 million, resulting in a gross margin of 39.9%. Gross profit for the second quarter of 2016 was \$10.6 million, resulting in a gross margin of 51.3%. This included \$3.6 million of contractual revenue at 100% gross margin. Excluding this contractual revenue and related margin, adjusted gross margin for the second quarter of 2016 would have been 41.1%. Adjusted gross margin is not meant to be considered in isolation or as a substitute for gross margin. Adjusted gross margin is subject to limitations and should be read only in conjunction with the Company's condensed consolidated financial statements prepared in accordance with GAAP.

Operating expenses for the second quarter of 2017 totaled \$32.4 million, compared to \$28.7 million for the second quarter of 2016. Operating expenses for the second quarter of 2017 and 2016 included non-cash stock-based compensation of \$4.4 million and \$4.5 million, respectively.

Net loss for the second quarter of 2017 was \$25.5 million, compared to \$18.5 million for the second quarter of 2016.

Cash, cash equivalents and investments, excluding restricted cash, at June 30, 2017 totaled \$102.6 million, compared to \$72.0 million at December 31, 2016.

**Quarterly Conference Call Information**

Management will host a quarterly conference call to discuss its second quarter 2017 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330, using an Audience Passcode of 6231-3559. The call will be webcast live and will be available for replay at Pacific Biosciences' website at <http://investor.pacificbiosciences.com/>.

**About Pacific Biosciences**

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT<sup>®</sup>) Technology, Pacific Biosciences' products enable: *de novo* genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio<sup>®</sup> sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at [www.pacb.com](http://www.pacb.com)

**Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences' potential development of products, future uses, quality or performance of, or benefits of using, products or technologies and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences' control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences' most recent filings with the Securities and Exchange

---

Commission, including Pacific Biosciences' most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption "Risk Factors." Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

**Contact:**

Trevin Rard

650.521.8450

[ir@pacificbiosciences.com](mailto:ir@pacificbiosciences.com)

---

**Pacific Biosciences of California, Inc.**  
**Unaudited Condensed Consolidated Statement of Operations**  
*(amounts in thousands, except per share amounts)*

	Three Months Ended June 30,		Six Months Ended June 30,	
	2017	2016	2017	2016
<b>Revenue:</b>				
Product revenue \$	16,548	\$ 13,587	\$ 37,842	\$ 25,966
Service and other revenue	3,525	3,564	7,146	6,716
Contractual revenue	—	3,596	—	7,192
Total revenue	20,073	20,747	44,988	39,874
<b>Cost of Revenue:</b>				
Cost of product revenue	8,155	7,115	19,517	13,995
Cost of service and other revenue	3,917	2,988	8,533	5,731
Total cost of revenue	12,072	10,103	28,050	19,726
Gross profit	8,001	10,644	16,938	20,148
<b>Operating Expense:</b>				
Research and development	16,883	17,522	33,854	33,883
Sales, general and administrative	15,505	11,192	30,770	22,900
Total operating expense	32,388	28,714	64,624	56,783
Operating loss	(24,387)	(18,070)	(47,686)	(36,635)
Interest expense	(826)	(795)	(1,664)	(1,574)
Other income (expense), net	(326)	366	(56)	358
Net loss	\$ (25,539)	\$ (18,499)	\$ (49,406)	\$ (37,851)
Basic and diluted net loss per share	\$ (0.26)	\$ (0.21)	\$ (0.52)	\$ (0.44)
Shares used in computing basic and diluted net loss per share	97,360	88,148	95,177	85,876

**Pacific Biosciences of California, Inc.**  
**Unaudited Condensed Consolidated Balance Sheets**  
*(amounts in thousands)*

	<b>June 31,</b>	<b>December 31,</b>
	<b>2017</b>	<b>2016</b>
<b>Assets</b>		
Cash and investments	\$ 102,596	\$ 71,978
Accounts receivable	9,525	11,421
Inventory	17,266	15,634
Prepaid and other current assets	3,545	9,978
Property and equipment	40,289	14,560
Long-term restricted cash	4,500	4,500
Other long-term Assets	184	9,813
<b>Total Assets</b>	<b>\$ 177,905</b>	<b>\$ 137,884</b>
<b>Liabilities and Stockholders' Equity</b>		
Accounts payable	\$ 6,514	\$ 8,359
Accrued expenses	17,840	16,604
Deferred service revenue	8,078	8,427
Deferred rent	14,599	19
Other liabilities	1,915	3,345
Financing derivative	15	356
Notes payable	13,084	16,106
Stockholders' equity	115,860	84,668
<b>Total Liabilities and Stockholders' Equity</b>	<b>\$ 177,905</b>	<b>\$ 137,884</b>